Neuropsychopharmacology
April 27, 2018
Inés Ibarra‐Lecue, Irene Mollinedo-Gajate, J. Javier Meana et al.
78 citations
Long-term use of potent cannabis during adolescence increases the risk of developing schizophrenia later in life, but to date, the mechanisms involved remain unknown. Several findings suggest that the functional selectivity of serotonin 2A receptor (5-HT2AR) through inhibitory G-proteins is involved in the molecular mechanisms responsible for psychotic symptoms. Moreover, this receptor is...
Translational Psychiatry
April 25, 2018
Boris Guennewig, Maina Bitar, Ifeanyi Obiorah et al.
There is a strong association between cannabis use and schizophrenia but the underlying cellular links are poorly understood. Neurons derived from human-induced pluripotent stem cells (hiPSCs) offer a platform for investigating both baseline and dynamic changes in human neural cells. Here, we exposed neurons derived from hiPSCs to Δ9-tetrahydrocannabinol (THC), and identified diagnosis-specific...
Revista da Biologia
April 23, 2018
Carolina Quiñones Bueno
O conhecimento das alterações cognitivas decorrentes do consumo regular de cannabis é deficiente, em particular no que se refere a sua influência de ordem emocional. Neste estudo é revisado como o uso da cannabis pode levar a alterações neurológicas e perceptuais, em especial quanto ao reconhecimento de emoções e de situações ameaçadoras. São encontradas evidências de dessensibilização na...
International Journal of Research in Ayurveda and Pharmacy
April 19, 2018
G. S. Ram, C Murali Krishna, Darshan Kumar et al.
7 citations
Vijaya (Cannabis sativa Linn.) is associated with spiritual and medicinal aspect of Indian cultural heritage.Currently it is a controlled substance placed under Schedule-1 in the United Nations Convention on Psychotropic Substances due to its abusive & narcotic nature.Ayurveda, the science of life has details regarding Vijaya identification, cultivation techniques, collection method,...
International Journal of Drug Policy
April 9, 2018
Maziyar Ghiabi, Masoomeh Maarefvand, Hamed Bahari et al.
Iran is currently discussing cannabis and opium regulations, which could bring a legalisation of drug consumption through a state supervised system. The article engages with the question of cannabis by looking at the legal interpretation of religious authorities in the Islamic Republic of Iran. The choice of Iran is justified for several reasons: firstly, Iran has a long history of drug use and...
Cannabis and Cannabinoid Research
April 2, 2018
Muhammad Waqas, Frederick S. Barrett, Nicolas J. Schlienz et al.
37 citations
Introduction: Cannabis has been historically classified as a hallucinogen. However, subjective cannabis effects do not typically include hallucinogen-like effects. Empirical reports of hallucinogen-like effects produced by cannabis in controlled settings, particularly among healthy research volunteers, are rare and have mostly occurred after administration of purified Δ-9 tetrahydrocannabinol...
Synapse
April 2018
Benjamin B Tournier, Andrea Dimiziani, Stergios Tsartsalis et al.
The Roman high (RHA)- and low (RLA)-avoidance rat sublines have been identified as an addiction-prone and addiction-resistant phenotype based on their high vs. low locomotor responsiveness to novelty and high vs. low ability to develop neurochemical and behavioral sensitization to psychostimulants, respectively. Most studies though have focused on psychostimulants and little is known about the...
Schizophrenia Bulletin
April 1, 2018
Jordi Soler García, Bárbara Arias, Jorge Moya et al.
Abstract Background The ZNF804A gene and cannabis use are risk factors for psychosis, both of which have also been associated with schizotypic traits. This study aimed to test whether ZNF804A (rs1344706) modulates the relation between cannabis use and schizotypy levels in a general population sample. Methods The sample consisted of 389 Spanish non-clinical subjects (43% males, mean...
Schizophrenia Bulletin
April 1, 2018
Caterina la Cascia, L. Ferraro, Fabio Seminerio et al.
Abstract Background Patients presenting to psychiatric services with their first episode of psychosis (FEP) report higher rates of previous cannabis use than the general population (Donoghue et al., 2011; Myles, Myles and Large, 2016). Evidence suggested that patients suffering from psychosis with a history of cannabis use have an earlier age of onset of psychosis (AOP) than those who never...
Schizophrenia Bulletin
April 1, 2018
Luccas Coutinho, Cinthia H Higuchi, Daniel A. Cavalcante et al.
Abstract Background Psychotic disorders induced by cannabis may present distinct symptomatic profile, course and underlying biology. Most studies on symptomatic effects of cannabis exposure are limited by examining patients after antipsychotic treatment. We investigated if antipsychotic naive FEP patients that reported cannabis use present higher symptom’s severity and if affects deferentially...